OssDsign AB (publ)

OM:OSSD Stock Report

Market Cap: SEK 771.5m

OssDsign Valuation

Is OSSD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OSSD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OSSD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OSSD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OSSD?

Key metric: As OSSD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OSSD. This is calculated by dividing OSSD's market cap by their current revenue.
What is OSSD's PS Ratio?
PS Ratio6.1x
SalesSEK 127.49m
Market CapSEK 771.51m

Price to Sales Ratio vs Peers

How does OSSD's PS Ratio compare to its peers?

The above table shows the PS ratio for OSSD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.7x
BACTI B Bactiguard Holding
4.9x7.2%SEK 1.2b
XVIVO Xvivo Perfusion
19x29.4%SEK 14.2b
IMS Invent Medic Sweden
4.9xn/aSEK 32.9m
BIOWKS Bio-Works Technologies
1.8xn/aSEK 68.6m
OSSD OssDsign
6.1x24.9%SEK 771.5m

Price-To-Sales vs Peers: OSSD is good value based on its Price-To-Sales Ratio (6.1x) compared to the peer average (7.7x).

Price to Sales Ratio vs Industry

How does OSSD's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

12 CompaniesPrice / SalesEstimated GrowthMarket Cap
ARJO B Arjo
0.8x3.6%US$837.96m
CARE Careium
0.8x10.2%US$65.04m
BOUL Boule Diagnostics
0.5x5.6%US$24.11m
ARCOMA Arcoma
0.8x8.3%US$12.68m
OSSD 6.1xIndustry Avg. 4.7xNo. of Companies12PS048121620+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: OSSD is expensive based on its Price-To-Sales Ratio (6.1x) compared to the Swedish Medical Equipment industry average (4.8x).

Price to Sales Ratio vs Fair Ratio

What is OSSD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OSSD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.1x
Fair PS Ratio8.9x

Price-To-Sales vs Fair Ratio: OSSD is good value based on its Price-To-Sales Ratio (6.1x) compared to the estimated Fair Price-To-Sales Ratio (8.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OSSD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 7.90
SEK 12.00
+51.9%
6.8%SEK 13.00SEK 11.00n/a3
Nov ’25SEK 6.48
SEK 12.33
+90.3%
10.1%SEK 14.00SEK 11.00n/a3
Oct ’25SEK 6.58
SEK 12.33
+87.4%
10.1%SEK 14.00SEK 11.00n/a3
Sep ’25SEK 7.43
SEK 12.33
+66.0%
10.1%SEK 14.00SEK 11.00n/a3
Aug ’25SEK 9.14
SEK 13.17
+44.1%
15.3%SEK 16.00SEK 11.50n/a3
Jul ’25SEK 9.26
SEK 13.17
+42.2%
15.3%SEK 16.00SEK 11.50n/a3
Jun ’25SEK 9.54
SEK 13.17
+38.0%
15.3%SEK 16.00SEK 11.50n/a3
May ’25SEK 9.74
SEK 13.33
+36.9%
14.5%SEK 16.00SEK 11.50n/a3
Apr ’25SEK 10.10
SEK 13.75
+36.1%
15.1%SEK 16.00SEK 11.00n/a4
Mar ’25SEK 8.92
SEK 13.75
+54.1%
15.1%SEK 16.00SEK 11.00n/a4
Feb ’25SEK 8.92
SEK 13.63
+52.7%
13.1%SEK 15.50SEK 11.00n/a4
Jan ’25SEK 8.00
SEK 14.67
+83.3%
5.8%SEK 15.50SEK 13.50n/a3
Dec ’24SEK 6.22
SEK 14.67
+135.8%
5.8%SEK 15.50SEK 13.50n/a3
Nov ’24SEK 5.80
SEK 14.50
+150.0%
12.3%SEK 16.00SEK 12.00SEK 6.483
Oct ’24SEK 6.46
SEK 14.50
+124.5%
12.3%SEK 16.00SEK 12.00SEK 6.583
Sep ’24SEK 5.54
SEK 13.17
+137.7%
14.0%SEK 15.50SEK 11.00SEK 7.433
Aug ’24SEK 6.06
SEK 12.50
+106.3%
17.0%SEK 15.50SEK 11.00SEK 9.143
Jul ’24SEK 5.02
SEK 12.50
+149.0%
17.0%SEK 15.50SEK 11.00SEK 9.263
Jun ’24SEK 4.87
SEK 12.50
+156.7%
17.0%SEK 15.50SEK 11.00SEK 9.543
May ’24SEK 4.94
SEK 12.50
+153.0%
17.0%SEK 15.50SEK 11.00SEK 9.743
Apr ’24SEK 4.82
SEK 12.50
+159.6%
17.0%SEK 15.50SEK 11.00SEK 10.103
Mar ’24SEK 5.10
SEK 12.50
+145.1%
17.0%SEK 15.50SEK 11.00SEK 8.923
Feb ’24SEK 5.59
SEK 12.73
+127.8%
25.4%SEK 15.50SEK 8.20SEK 8.923
Jan ’24SEK 5.82
SEK 12.73
+118.8%
25.4%SEK 15.50SEK 8.20SEK 8.003
Dec ’23SEK 4.90
SEK 12.73
+159.9%
25.4%SEK 15.50SEK 8.20SEK 6.223
Nov ’23SEK 4.10
SEK 13.17
+221.5%
19.9%SEK 15.50SEK 9.50SEK 5.803

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Arcoma

SEK 138.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 10.50

7D

-2.3%

1Y

42.9%

Dignitana

SEK 85.4m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.06

7D

-1.9%

1Y

-49.5%

Mentice

SEK 529.3m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 20.70

7D

-17.5%

1Y

-50.7%